Skip to main content
LLY
NYSE Life Sciences

Lilly's Mounjaro Tops Other GLP-1s for Type 2 Diabetes Patients in New Trial

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,129.025
Mkt Cap
$1.063T
52W Low
$623.78
52W High
$1,149.1
52W Position info
81% above low
Off High info
1.7% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LLY sits 81% above its 52-week low of $623.78.

Summary

Eli Lilly's Mounjaro demonstrated superior efficacy over other GLP-1 drugs, including Novo Nordisk's semaglutide, in the SURPASS-EARLY trial. The study showed Mounjaro led to significantly better blood sugar control, weight reduction, and waist circumference improvements for type 2 diabetes patients not responding to initial treatment. Roughly 60% of Mounjaro patients achieved normal blood sugar levels after two years, compared to 24% in the control group. This new clinical data reinforces Mounjaro's competitive advantage and strengthens Eli Lilly's leadership in the rapidly growing GLP-1 market, following the company's exceptional Q1 2026 results driven by strong Mounjaro sales.

At the time of this announcement, LLY was trading at $1,129.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 18, 2026, 3:04 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,381.18
Real-time Price: $1,352.07 info
Change: -$29.11 (-2%) info
Market Cap: $1.271T info
LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,352.07 info
Change: -$64.15 (-5%) info
Market Cap: $1.271T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,352.07 info
Change: -$103.29 (-7%) info
Market Cap: $1.271T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,352.07 info
Change: -$100.62 (-7%) info
Market Cap: $1.271T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,352.07 info
Change: -$95.78 (-7%) info
Market Cap: $1.271T info